导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.28% | 1689/4773 |
| 近一周 | -2.51% | 2409/5462 |
| 近一月 | -5.03% | 2992/5421 |
| 近一季 | -8.99% | 3057/5209 |
| 近半年 | -7.00% | 3166/4920 |
| 近一年 | 6.34% | 1473/4366 |
| 近两年 | 66.86% | 1035/2954 |
| 近三年 | 33.37% | 920/2253 |
| 成立以来 | 61.33% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.19% 1020/4961 |
17.72% 1456/5312 |
- - |
- - |
| 2025 | 28.71% 1460/4813 |
2.04% 1483/3635 |
1.75% 2176/4076 |
23.10% 1580/4524 |
0.69% 1841/4813 |
| 2024 | 6.42% 1755/3463 |
-2.73% 1417/2808 |
-5.05% 1627/3014 |
15.03% 1834/3129 |
0.17% 1256/3463 |
| 2023 | -6.55% 858/2656 |
7.14% 599/2280 |
-4.16% 1076/2385 |
-4.61% 1178/2515 |
-4.59% 1108/2655 |
| 2022 | -17.96% 645/2207 |
-13.35% 742/1919 |
3.05% 1226/2016 |
-10.32% 383/2113 |
2.46% 930/2208 |
| 2021 | 14.31% 340/1822 |
-1.51% 506/1255 |
8.38% 627/1330 |
4.09% 382/1466 |
2.88% 505/1822 |
| 2020 | - - |
- - |
- - |
11.14% 474/1164 |
2.87% 959/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 中银证券中证500ETF联接C VS. 长安沪深300非周期A(740101) |